Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8461 to 8475 of 8990 results

  1. Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]

    In development Reference number: GID-TA11631 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development Reference number: GID-IPG10394 Expected publication date: TBC

    Interventional procedures guidance
    In development

  3. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued Reference number: GID-TAG494

    Technology appraisal guidance
    Discontinued

  5. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]

    In development Reference number: GID-TA11482 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6436]

    In development Reference number: GID-TA11567 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development Reference number: GID-TA11443 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]

    In development Reference number: GID-TA11880 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]

    In development Reference number: GID-TA11913 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    Discontinued Reference number: GID-TA11086

    Technology appraisal guidance
    Discontinued

  11. VTS-270 for treating Niemann-Pick type C1 [ID1267]

    Discontinued Reference number: GID-HST10020

    Highly specialised technologies guidance
    Discontinued

  12. Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]

    In development Reference number: GID-TA11882 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

    In development Reference number: GID-TA11560 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]

    Discontinued Reference number: GID-TA11163

    Technology appraisal guidance
    Discontinued

  15. Benralizumab for previously treated severe nasal polyps [ID1659]

    Discontinued Reference number: GID-TA10818

    Technology appraisal guidance
    Discontinued